Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ARLZQ...007...Chart...Psar flipped to a Bullish Buy Position...Pincher squeezing here on strong green volume...
https://www.otcmarkets.com/stock/ARLZQ/news/story?e&id=1251064
https://c.stockcharts.com/c-sc/sc?s=ARLZQ&p=D&yr=0&mn=3&dy=10&i=p33204496947&a=638327862&r=1546510319183
How do you buy this one just don’t want to buy it blindly and get crushed?
Price is 0.01 again. Thanks for the cheapies.
...$ARLZQ...15 X Average daily volume ! https://www.otcmarkets.com/stock/ARLZQ/quote
Yep - or maybe they keep it and re-fund the company then come out of Chap 11.
As predicted there was nothing on the way back up to the penny. Some retail just gave away their shares - could not resist the 1 day profit from 0.0015 (not me).
This deal will attract a lot investor$ : "The Company and certain of its affiliates continue to seek approval of the U.S. Bankruptcy Court for the sale of its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P. ("Deerfield"), in a transaction valued at U.S.$130 million "
762k bids 0.005. See you back at .01 shortly.
0.005 fib pullback from 0.0115. Bidders stalk now.
more like news coming leak ,usually someone tells their friends and family buy this up great news is coming ,huge vol spike and then next day big news comes out
Nice price 0.0055 if you believe this can recover.
If you say so. Check volume on buy versus pullback.
From the conversation link..
"Total debt = $285M - $110M(Vimovo+Canada)=$175M , which $75M is senior secure convertible note with 2.5% interest and ARLZ could issue another $100M senior secure Note with 2.5% then company will emerge from BK with a nice pipeline (Toprol-XL , Zontivity , Fibicore and US right for Bezalip SR and Yosprala) Toprol keep bring cash and other drug could be licensed out and bring a lot of cash . This is a WIN-WIN GAME ! still Optimism. Happy new year!"
when someone buys the Toprol-xl franchise they are going to need a ticker symbol , I am betting that's the plan in action ,hence the $40k traded today
""Following a thorough financial and strategic review, we believe that these sales, together with an auction process under court supervision are in the best interests of the Company and its stakeholders," said Adrian Adams, Chief Executive Officer of Aralez."
https://ir.aralez.com/news-releases/news-release-details/aralez-pharmaceuticals-enter-purchase-agreements-sell
Buying opp here, low volume on shake down.
Penny to get in here now. Could be a lot more tomorrow.
operative word is usually...watching and hoping for substantiation of share status
Omnibus hearing Date : January 10, 2019 at 10:00 a.m. (Eastern Time)
https://cases.primeclerk.com/Aralez/
Upcoming soon imho : The Company and certain of its affiliates continue to seek approval of the U.S. Bankruptcy Court for the sale of its TOPROL-XL® Franchise to its secured lender, certain funds managed by Deerfield Management Company, L.P. ("Deerfield"), in a transaction valued at U.S.$130 million
Little more pressure on the ASK and squeeze effect could put $ARLZQ orbitally nuts :)
$ARLZQ: This is $BIOAQ like in Every single way
If you don't see it... then you just don't know it.
At a minimum, we get to $0.06... I can feel it.
GO $ARLZQ
you called it ,thru .01 ,more scanners lit up nhod will bring more ppl
$ARLZQ: BOOOOOOOOOOMmmmmmmmmmm... Penny Breaker baby !
How you Like them APPLES NOW :)
What a great start to 2019 !
LOVE IT
GO $ARLZQ
410k bidder on 0.0088. Ticked a penny.
ARLZQ 4xs ave vol. hitting scanners ,btw thanks ezmoney for the tip and info , your da bomb!!!
$ARLZQ: Its about to crack $0.01 again any minute
Watch and observe.
Congrats to the Entries at $0.0014-$0.002
You know how its done.
This $BIOAQ version 2 in effect
GO $ARLZQ
Late post I was in Friday, looking GOOD!
even if a short has to pay .10 ,most shorted from way higher ,they still going to do good ,but its going to be harder to get shares at a higher price so it keeps running up ,gotta love Qs
shorts need shares and the float is so low ,could run insane high ,we have seen these before ezmoney
$ARLZQ: Could be that NUVO-Pharma lets Aralez ride
On its own status when they complete the takeover.
Why not.
Bet NUVO was buying shares of $ARLZQ on the way down just for that purpose.
GO $ARLZQ
$ARLZQ: Going like $BIOAQ did last year
This is the new $BIOAQ mover
GO $ARLZQ
$ARLZQ: $0.009s going......... Shes a RUNNER !!!!!!
GO $ARLZQ
$ARLZQ: $0.006s going............ Massive Squeezer in effect
Squeeze them all out........ running to $0.01 easy
GO $ARLZQ
$ARLZQ: $0.005s going... market caught onto news
Lets roll now......... time for that $BIOAQ like squeeze.
GO $ARLZQ
$ARLZQ: Hitting $0.0022... here come $0.0028s
GOOooooooooooooooooooooooooo
Runner baby !
GO $ARLZQ
Toprol-xl(R)franchise still for sale ,a co. looking for a ticker could buy ARLZQ ,low float ,valued 130ml
Q,s can run up crazy on news like this , I made a killing on bioa@ / soup@ and many others ,I am throwing a $k at this Q too
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
470
|
Created
|
02/05/16
|
Type
|
Free
|
Moderators |
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. It also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women?s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, its out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company is headquartered in Milton, Canada.
Aralez Pharmaceuticals Inc.’s ISS Governance QualityScore as of March 2, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 9.
151 Steeles Avenue East
Milton, ON L9T 1Y1
Canada
905-876-1118
http://www.aralez.com
Sector:
Industry:
Full Time Employees:
Name | Title | Pay | Exercised | Age |
---|---|---|---|---|
Mr. Adrian Adams | Chief Exec. Officer and Director | 1.02M | N/A | 66 |
Mr. Andrew I. Koven | Pres and Chief Bus. Officer | 683.18k | N/A | 59 |
Mr. Scott J. Charles | Chief Financial Officer | 653.07k | N/A | 42 |
Mr. Mark A. Glickman | Chief Commercial Officer | 504.94k | N/A | 51 |
Mr. John E. Barnhardt CPA | Principal Accounting Officer and VP of Fin. & Admin. | N/A | N/A | 67 |
SHARE THIS ARTICLE
-First Quarter 2017 Net Revenues of $26.0 Million-
-Cost Savings Plan Expected to Reduce 2017 Expenses by $23.0 Million; Improved 2017 Adjusted EBITDA Guidance-
-Currently Implementing a Bold Program Aimed at Allowing All Patients to Access Yosprala for Only $10.00 Per Month-
MISSISSAUGA, Ontario, May 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced financial results for the first quarter ended March 31, 2017. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
"We are pleased to report a solid first quarter of 2017, together with important updates to our business addressing a number of the challenges we face," said Adrian Adams, Chief Executive Officer of Aralez. "We are making a bold and significant change to our pricing strategy for Yosprala® aimed at allowing all patients to access the product for only $10.00 per month. In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year. We also continue to opportunistically look at business development opportunities with a strong focus on value creating and transformative M&A with the goal of enhancing shareholder value."
Company Highlights:
"Deerfield Partners remains fully supportive of Aralez and its management team as the company navigates its way through recent challenges," said James Flynn, Managing Partner at Deerfield. "We are encouraged by the new pricing strategy for Yosprala and the prospects for Zontivity."
Cost Savings Initiatives
The Company previously announced in April 2017 that it had begun implementing cost savings initiatives as part of the Company's ongoing objective to maximize value from its assets and preserve financial flexibility. The total expected operating expense reduction in 2017 of approximately $23.0 million includes the previously announced 32% reduction in its U.S. sales force, which is expected to yield 2017 savings of approximately $5.5 million ($7.5 million on an annual basis), a decrease of approximately $9.0 million in 2017 commercial spend, which primarily relates to non-direct marketing spend on Yosprala, and decreased 2017 departmental expenses across the business of approximately $8.5 million. While Aralez has made significant reductions to its expenses, the Company plans to invest an additional $7.0 million to support a successful phased launch of Zontivity that commenced on April 24, 2017, which the Company views as an increasingly attractive opportunity. The Company also continues to assess various business development opportunities with the goal of providing improved cash flow and an enhanced platform for creating value.
First Quarter 2017 Financial Results
Aralez's financial results for the three months ended March 31, 2016 include the operations of Tribute Pharmaceuticals Canada Inc. (Tribute) from February 5, 2016, the closing date of the Pozen and Tribute merger transaction (the Merger), through March 31, 2016, but do not include the results of Zontivity or Toprol-XL and its currently marketed authorized generic (the Toprol-XL franchise) as these acquisitions were completed on September 6, 2016 and October 31, 2016, respectively. Aralez's financial results for the three months ended March 31, 2017 include the results of Tribute, Zontivity and the Toprol-XL franchise.
Total revenues for the three months ended March 31, 2017 were $26.0 million compared to $8.1 million for the three months ended March 31, 2016. Net product revenues of $6.7 million for the three months ended March 31, 2017 primarily related to the product portfolio acquired with the acquisition of Tribute as well as net product revenues from Yosprala and Fibricor®. Other revenues of $19.3 million for the three months ended March 31, 2017 were comprised of net revenues of $15.6 million from the acquisitions of the Toprol-XL franchise and Zontivity, which are recorded net of related cost of product revenues and fees paid during the respective transition service periods, and Vimovo® royalties of $3.7 million. Pursuant to the Company's agreement with Horizon in the U.S., subject to certain conditions described in our public filings, Aralez is guaranteed a quarterly minimum royalty amount (calculated based on a minimum annual royalty of $7.5 million), which was reflected in the Company's first quarter results. Net product revenues of $3.6 million for the three months ended March 31, 2016 related to the Tribute product portfolio acquired in the Merger, which was completed on February 5, 2016. Other revenues of $4.5 million for the three months ended March 31, 2016 were comprised solely of Vimovo royalties.
Cost of product revenues were $2.8 million for the three months ended March 31, 2017 compared to $2.5 million for the three months ended March 31, 2016. The increase related primarily to costs of product revenues for the full quarter in 2017 from the Company's product portfolio that was acquired as part of the Merger in February 2016.
SG&A expenses were $30.8 million for the three months ended March 31, 2017 compared to $37.5 million for the three months ended March 31, 2016. The decrease in SG&A expenses was primarily driven by costs related to the Merger in the prior year of approximately $19.4 million, partially offset by increased costs related to the build out of our U.S. sales force in 2016 and increased promotional expenses in the U.S. during the first quarter of 2017.
R&D expenses for the three months ended March 31, 2017 were $0.1 million compared to $4.4 million for the three months ended March 31, 2016. The decrease related primarily to higher costs incurred in the first quarter of 2016 for Yosprala in advance of its U.S. approval in September 2016.
Amortization of intangible assets of $8.5 million for the three months ended March 31, 2017 related to the acquisitions of Tribute, Zontivity and the Toprol-XL franchise. Amortization of intangible assets for the three months ended March 31, 2016 of $1.3 million related solely to the acquisition of Tribute.
The change in fair value of contingent consideration of $4.4 million for the three months ended March 31, 2017 related to accretion for the Toprol-XL franchise and Zontivity acquisitions. There was no expense related to fair value changes in contingent consideration for the three months ended March 31, 2016.
Interest expense of $6.7 million for the three months ended March 31, 2017 was primarily attributable to the borrowing of $200 million under the Company's credit facility in the fourth quarter of 2016 in connection with the acquisitions of Zontivity and the Toprol-XL franchise and $75 million convertible notes. Interest expense of $0.3 million for the three months ended March 31, 2016 related to the $75 million convertible notes.
Other income, net for the three months ended March 31, 2017, was $0.4 million compared to $4.8 million for the three months ended March 31, 2016, a decrease of $4.4 million. The decrease principally related to a $4.6 million decrease in the fair value of the warrants liability acquired from Tribute during the prior year, offset by a $0.3 million gain from the sale of a building in London, Ontario during the three months ended March 31, 2017.
The net loss for the three months ended March 31, 2017 was $27.5 million, or $0.42 loss per share on a fully diluted basis, compared to a net loss for the three months ended March 31, 2016 of $33.8 million, or $0.73 loss per share on a fully diluted basis.
Adjusted EBITDA was ($3.6) million for the three months ended March 31, 2017 compared to Adjusted EBITDA of ($11.1) million for the three months ended March 31, 2016.
Balance Sheet
As of March 31, 2017, approximately 65.8 million of the Company's common shares were issued and outstanding and the Company had cash and cash equivalents of approximately $73.7 million.
Updated 2017 Guidance
Aralez's estimates are based on projected results of the Company for the year ending December 31, 2017 and reflect management's current beliefs and expectations about, among other things, prescription trends, competition, pricing levels, inventory levels, and anticipated future events. The Company's guidance on Adjusted EBITDA includes, among other things, costs to support the commercialization efforts with respect to Yosprala, Zontivity and the Canadian product portfolio as well as costs to support the global corporate structure. It excludes share-based compensation expense and certain discrete costs, including merger and product acquisition-related expenses. See "Use of Non-GAAP Financial Measures" below.
For the year ending December 31, 2017, assuming, among other factors more particularly set out in "Cautionary Note Regarding Forward-Looking Statements" below, the Company currently expects:
See the table below for a comparison of the Company's original 2017 guidance compared to the updated 2017 guidance:
Measure | 2017 Original Guidance | 2017 Updated Guidance |
Net Revenues | $80 million to $100 million | $80 million to $100 million |
Adjusted EBITDA | $(25) million to $(10) million | $(5) million to $5 million |
First Quarter Results Webcast
Aralez will host a webcast this morning, May 9, 2017 at 9:00 a.m. ET to present results for the first quarter 2017. The webcast can be accessed live and will be available for replay at www.aralez.com.
Conference Call Details
Date: Tuesday, May 9, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |